{"nctId":"NCT00403260","briefTitle":"Pyronaridine - Artesunate (3:1) Versus Mefloquine Plus Artesunate in Plasmodium Falciparum Malaria Patients","startDateStruct":{"date":"2007-01","type":"ACTUAL"},"conditions":["Falciparum Malaria"],"count":1271,"armGroups":[{"label":"Pyronaridine - artesunate","type":"EXPERIMENTAL","interventionNames":["Drug: Pyronaridine - artesunate"]},{"label":"Mefloquine plus artesunate","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Mefloquine plus artesunate"]}],"interventions":[{"name":"Pyronaridine - artesunate","otherNames":["Pyramax"]},{"name":"Mefloquine plus artesunate","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female patients between the ages of 3 and 60 years, inclusive.\n* Body weight between 20 kg and 90 kg with no clinical evidence of severe malnutrition.\n* Presence of acute uncomplicated P. falciparum mono-infection confirmed by:\n\n  1. Fever, as defined by axillary/tympanic temperature ≥37.5°C or oral/rectal temperature ≥38°C, or documented history of fever in the previous 24 hours and,\n  2. Positive microscopy of P. falciparum with parasite density between 1,000 and 100,000 asexual parasite count/µl of blood\n* Written informed consent provided by patient and/or parent/guardian/spouse.\n* Ability to swallow oral medication.\n\nExclusion Criteria:\n\n* Patients with signs and symptoms of severe/complicated malaria requiring parenteral treatment according to the World Health Organization Criteria 2000.\n* Mixed Plasmodium infection.\n* Severe vomiting or severe diarrhoea.\n* Known history or evidence of clinically significant disorders.\n* Presence of significant anaemia, as defined by Hb \\<8 g/dL.\n* Presence of febrile conditions caused by diseases other than malaria.\n* Known history of hypersensitivity, allergic or adverse reactions to pyronaridine, mefloquine or artesunate or other artemisinins.\n* Use of any other antimalarial agent within 2 weeks prior to start of the study as evidenced by positive urine test.\n* Female patients of child-bearing potential must be neither pregnant (as demonstrated by a negative pregnancy test) nor lactating, and must be willing to take measures to not become pregnant during the study period.\n* Presence of significant renal or hepatic impairment.\n* Receipt of an investigational drug within the past 4 weeks.\n* Known active Hepatitis A IgM, Hepatitis B surface antigen or Hepatitis C antibody.\n* Known seropositive HIV antibody.\n* Previous participation in any clinical study with PA.","healthyVolunteers":false,"sex":"ALL","minimumAge":"3 Years","maximumAge":"60 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Subjects With PCR-corrected Adequate Clinical and Parasitological Response (ACPR) on Day 28","description":"Percentage of subjects with PCR-corrected adequate clinical and parasitological response (ACPR) on Day 28, defined as absence of parasitaemia on Day 28 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.2","spread":null},{"groupId":"OG001","value":"98.1","spread":null}]}]}]},{"type":"SECONDARY","title":"PCR-corrected ACPR on Day 14","description":"Percentage of subjects with PCR-corrected adequate clinical and parasitological response (ACPR) on Day 14, defined as absence of parasitaemia on Day 14 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.9","spread":null},{"groupId":"OG001","value":"99.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Crude ACPR on Days 14 and 28","description":"Percentage of subjects with adequate clinical and parasitological response (ACPR) on Days 14 and 28, without correction by PCR, defined as absence of parasitaemia on Days 14 and 28 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.9","spread":null},{"groupId":"OG001","value":"99.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.7","spread":null},{"groupId":"OG001","value":"96.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Parasite Clearance Time","description":"Parasite clearance time was defined as the time from first dosing to time of first blood draw with parasite clearance. Parasite clearance was defined as zero presence of asexual parasites for 2 consecutive negative readings taken between 7 and 25 hours apart.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.7","spread":null},{"groupId":"OG001","value":"32.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Fever Clearance Time","description":"Fever clearance time was defined as the time from first dosing to first normal reading of temperature (\\<37.5°C taken axillary or tympanic; \\<38°C taken oral or rectal) for 2 consecutive normal temperature readings taken between 7 and 25 hours apart.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.9","spread":null},{"groupId":"OG001","value":"16.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Parasite Clearance at Day 1, 2 and 3","description":"Parasite clearance time was defined as the time from first dosing to the time of first blood draw with parasite clearance. Parasite clearance was defined as zero presence of asexual parasites for 2 consecutive negative readings taken between 7 and 25 hours apart.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.5","spread":null},{"groupId":"OG001","value":"31.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.8","spread":null},{"groupId":"OG001","value":"79.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.5","spread":null},{"groupId":"OG001","value":"90.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Fever Clearance at Day 1, 2 and 3","description":"Fever clearance time was defined as the time for at least 2 consecutive normal body temperature measurements (\\<37.5°C axillary/tympanic or \\<38.0°C oral/rectal) to be obtained within an interval of 7 to 25 hours post-dosing.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.5","spread":null},{"groupId":"OG001","value":"78.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.9","spread":null},{"groupId":"OG001","value":"96.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.2","spread":null},{"groupId":"OG001","value":"98.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Adverse Events and Clinically Significant Laboratory Results","description":"Cases and severity of adverse events and of clinically significant laboratory results, ECG, vital signs or physical examination abnormalities","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"389","spread":null},{"groupId":"OG001","value":"190","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"153","spread":null},{"groupId":"OG001","value":"94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":848},"commonTop":["Headache","Myalgia","Dizziness","Anorexia","Anaemia"]}}}